Until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of
either aspirin or clopidogrel monotherapy. Now, by adding a low-dose DOAC to low-dose aspirin, medical therapy may reduce the need for major vascular surgery or endovascular procedures.
Join expert faculty live on April 4 to learn about the latest evidence, indications, and guideline-based utilization of dual antiplatelet therapy.
Thursday, April
4, 2019
12–1pm ET | 9–10am PT
Earn up to 1.00 AMA PRA Category 1 Credit™ of continuing education
